Kelly Hamm
Family · New Castle, INNPI 1629634746
Payments from drug & device makers
Across 283 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- AbbVie$736
- Otsuka America Pharmaceutical, Inc.$413
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$412
- Axsome Therapeutics, Inc.$306
- Lundbeck LLC$255
- plus $1K from 23 others
What the payments were for
- Food & beverage$5,64899%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 74 | $2,087 |
| AbbVie | 50 | $736 |
| Otsuka America Pharmaceutical, Inc. | 23 | $413 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $412 |
| Axsome Therapeutics, Inc. | 17 | $306 |
| Lundbeck LLC | 15 | $255 |
| Corium, LLC | 14 | $253 |
| Neurocrine Biosciences, Inc. | 9 | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $166 |
| Ironshore Pharmaceuticals Inc. | 8 | $146 |
| Johnson & Johnson | 6 | $116 |
| E.r. Squibb & Sons, L.L.C. | 5 | $80 |
| Bayer | 5 | $79 |
| Indivior Inc. | 4 | $79 |
| Tris Pharma Inc | 4 | $69 |
| Lilly USA, LLC | 3 | $44 |
| GSK | 3 | $41 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $25 |
| Biogen | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Antares Pharma, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$2,138
- ARISTADA$1,423
- ARISTADA INITIO$121
How this compares
$5,707 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 19 | $74,644 |
| CaplytaLumateperone Tosylate | 32 | $55,079 |
| VraylarCariprazine Hcl | 32 | $46,536 |
| TrintellixVortioxetine Hydrobromide | 55 | $43,870 |
| VivitrolNaltrexone Microspheres | 14 | $23,243 |
| Aripiprazole | 17 | $3,691 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 21 | $2,846 |
| Quetiapine Fumarate | 55 | $1,454 |
| Prazosin Hcl | 23 | $1,046 |
| Alprazolam | 81 | $972 |
| Hydroxyzine Hcl | 39 | $739 |
| Buspirone Hcl | 27 | $661 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $433 |
| Bupropion XlBupropion Hcl | 15 | $427 |
| Duloxetine Hcl | 19 | $409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada, Vivitrol | $2,087 | $97,88633 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $412 | $55,07932 claims |
| AbbVieVraylar | $736 | $46,53632 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $166 | $43,87055 claims |
| Lilly USA, LLCOlanzapine | $44 | $16816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in New Castle
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.